Dabigat
Generic Name
Dabigatran Etexilate Mesylate 110 mg Capsule
Manufacturer
Various (original by Boehringer Ingelheim)
Country
Global (Germany for original, varies for generics)
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| dabigat 110 mg capsule | ৳ 95.00 | ৳ 950.00 |
Description
Overview of the medicine
Dabigatran etexilate is an oral direct thrombin inhibitor used to prevent blood clots in various conditions like atrial fibrillation, deep vein thrombosis, and pulmonary embolism.
Uses & Indications
Dosage
Adults
For prevention of stroke in NVAF: 150 mg twice daily. For patients 80 years or older, or with moderate renal impairment (CrCl 30-50 mL/min), or at high risk of bleeding, 110 mg twice daily may be considered.
Elderly
For patients 80 years or older: 110 mg twice daily.
Renal_impairment
For CrCl 30-50 mL/min: 110 mg twice daily. Not recommended for CrCl <30 mL/min.
How to Take
Administer orally, with or without food. Swallow the capsule whole with a glass of water. Do not open, chew, or crush the capsule as this increases bioavailability and bleeding risk.
Mechanism of Action
Dabigatran etexilate is a prodrug that is converted to dabigatran, which is a potent, reversible, direct thrombin inhibitor. It prevents thrombin-mediated effects, including fibrin formation, activation of factors V, VIII, XI, and XIII, and platelet aggregation.
Pharmacokinetics
Onset
Anticoagulant effect seen within 0.5-2 hours.
Excretion
Primarily excreted unchanged via the kidneys (80%).
Half life
12-17 hours (increases with renal impairment).
Absorption
Rapidly absorbed and converted to dabigatran. Bioavailability is low (6.5%) after oral administration. Peak plasma concentrations 0.5-2 hours.
Metabolism
Primarily by esterase-catalyzed hydrolysis to active dabigatran. No major involvement of cytochrome P450 system.
Side Effects
Contraindications
- •Active pathological bleeding.
- •Severe renal impairment (CrCl <30 mL/min).
- •Mechanical prosthetic heart valve.
- •Hypersensitivity to dabigatran or excipients.
- •Concomitant use with other systemic anticoagulants.
Drug Interactions
Other anticoagulants
Increased bleeding risk (e.g., warfarin, heparin, antiplatelet agents).
P-glycoprotein (P-gp) inducers
Can decrease dabigatran plasma levels, reducing efficacy. Avoid concomitant use (e.g., rifampicin, St. John's wort).
P-glycoprotein (P-gp) inhibitors
Can increase dabigatran plasma levels, increasing bleeding risk. Dosage adjustment may be needed (e.g., amiodarone, verapamil, quinidine, clarithromycin).
Storage
Store at room temperature (20°C to 25°C), away from moisture and heat. Keep in original packaging until use.
Overdose
Overdose can lead to hemorrhagic complications. Specific reversal agent (idarucizumab) is available. Management includes general supportive measures, activated charcoal (if recent ingestion), and maintaining hydration.
Pregnancy & Lactation
Pregnancy Category C. Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Not recommended during breastfeeding due to lack of data and potential for serious adverse reactions in the infant.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
36 months from manufacturing date
Availability
Pharmacies, Hospitals
Approval Status
Approved by major regulatory bodies (e.g., FDA, EMA, DGDA)
Patent Status
Patent protected (original), generics emerging
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
